Parabilis Medicines targets $475 million in U.S. IPO

Investing.com -- Parabilis Medicines announced today that it plans to raise up to $475 million through a U.S. initial public offering. The biopharmaceutical company filed to offer 25 million shares priced between $17 and $19 each.

The company will list its shares on the Nasdaq exchange under the ticker PBLS.

Regeneron Pharmaceuticals agreed to purchase approximately $75 million of Parabilis Medicines' common stock through a concurrent private placement, the company said.

Parabilis Medicines plans to allocate about $150 million of the IPO proceeds toward the ongoing clinical development of zolucatetide for desmoid tumors. An additional $120 million will fund the continued clinical development of zolucatetide across several other indications. The company intends to use roughly $130 million to advance its pipeline of additional programs.

Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities, and LifeSci Capital are serving as underwriters for the offering.

You May Also Be Interested In

• U.S. debt tops $40 trillion
• SpaceX held talks to acquire AI coding startup Cognition - report
• NorthStrive Acquisition Corp I. Announces Closing of $100,000,000 Initial Public Offering